Treatment results of chemoradiation therapy for localized aggressive lymphomas: a retrospective 20-year study

[1]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[2]  M. Pfreundschuh,et al.  Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Chott,et al.  Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  H. Nakamine,et al.  Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin‐6 as independent predictors of prognosis in aggressive non‐Hodgkin's lymphoma , 2002, European journal of haematology.

[5]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[6]  A. Bezjak,et al.  Stage I and II MALT lymphoma: results of treatment with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[7]  H. Joensuu,et al.  Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.

[8]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[10]  G. Bonadonna,et al.  Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Jagannath,et al.  Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. , 1991, Blood.

[12]  R. Arriagada,et al.  The value of adjunctive radiotherapy when chemotherapy is the major curative method. , 1990, International journal of radiation oncology, biology, physics.

[13]  J. Connors,et al.  Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Jagannath,et al.  Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. , 1989, Blood.

[15]  G. Kerr,et al.  Influence of therapy on local control and survival in stage I and II intermediate and high grade non-Hodgkin's lymphoma. , 1988, European journal of cancer & clinical oncology.

[16]  S. Horning,et al.  Combined modality therapy for stage I-II large cell lymphoma. , 1987, International journal of radiation oncology, biology, physics.

[17]  M. Kaminski,et al.  Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. , 1986, Annals of internal medicine.

[18]  V. Devita,et al.  The effect of combined modality therapy on local control and survival. , 1986, International journal of radiation oncology, biology, physics.

[19]  D. Rosenthal,et al.  Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Hattori,et al.  Radiochemotherapy for non‐Hodgkin's lymphoma in palatine tonsil , 1984, Cancer.

[21]  W. Velasquez,et al.  Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas , 1984, Cancer.

[22]  T. Miller,et al.  Initial chemotherapy for clinically localized lymphomas of unfavorable histology. , 1983, Blood.

[23]  E. Freireich,et al.  Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types , 1980, Cancer.

[24]  G. Bonadonna,et al.  Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. , 1980, International journal of radiation oncology, biology, physics.

[25]  Stephen E. Jones,et al.  CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA , 1979, The Lancet.

[26]  S. Donaldson,et al.  Combined modality therapy in malignant lymphomas. , 1977, Cancer treatment reports.

[27]  Roger Williams,et al.  PARACETAMOL HEPATOXICITY , 1976, The Lancet.

[28]  N. Ahmadloo,et al.  Treatment results of tonsillar lymphoma: a 10-year experience , 2004, Annals of Hematology.

[29]  T. Conroy,et al.  Radiotherapy is unnecessary in elderly patients with localized agressive non Hodgkin's lymphoma: results of the LNH 93-4 study , 2002 .

[30]  A. Avilés,et al.  Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. , 1996, European journal of cancer. Part B, Oral oncology.

[31]  A. Kida,et al.  Clinical analysis of malignant lymphomas of tonsils. , 1996, Acta oto-laryngologica. Supplementum.

[32]  A. Piattelli,et al.  Head and neck non-Hodgkin's lymphomas. , 1995, European journal of cancer. Part B, Oral oncology.

[33]  National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. , 1982, Cancer.